Literature DB >> 15721475

Blockade of HERG channels by HIV protease inhibitors.

Blake D Anson1, Joel G R Weaver, Michael J Ackerman, Omobosola Akinsete, Keith Henry, Craig T January, Andrew D Badley.   

Abstract

The HIV protease inhibitor class of antiretroviral drug causes unpredicted adverse effects by changing elements of normal cellular metabolism. A case of QT prolongation in a patient receiving protease inhibitors made us question whether these drugs might be responsible. We identified 24 patients with QT prolongation or torsade de pointes, or both, associated with protease inhibitors, using the Food and Drug Administration's voluntary adverse event reporting system. Attending physicians thought that protease inhibitors were the most probable cause of these symptoms in 14 of the patients. Drug-induced QT prolongation is usually caused by block of human ether-a-go-go-related gene (HERG) potassium channels, and we showed that lopinavir, nelfinavir, ritonavir, and saquinavir caused dose-dependent block of HERG channels heterologously expressed in HEK293 cells in vitro. We also recorded block by lopinavir of repolarising potassium current (I(Kr)) channels in neonatal mouse cardiac myocytes. Our data show that four protease inhibitors block HERG channels, suggesting that protease inhibitors could predispose individuals to QT prolongation and torsade de pointes.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15721475     DOI: 10.1016/S0140-6736(05)17950-1

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  47 in total

1.  Prolongation of the QTc interval in HIV-infected individuals compared to the general population.

Authors:  Nico Reinsch; Marina Arendt; Marie Henrike Geisel; Christina Schulze; Volker Holzendorf; Anna Warnke; Till Neumann; Norbert H Brockmeyer; Dirk Schadendorf; Lewin Eisele; Raimund Erbel; Susanne Moebus; Karl-Heinz Jöckel; Stefan Esser
Journal:  Infection       Date:  2017-08-03       Impact factor: 3.553

2.  Binding of novel fullerene inhibitors to HIV-1 protease: insight through molecular dynamics and molecular mechanics Poisson-Boltzmann surface area calculations.

Authors:  Haralambos Tzoupis; Georgios Leonis; Serdar Durdagi; Varnavas Mouchlis; Thomas Mavromoustakos; Manthos G Papadopoulos
Journal:  J Comput Aided Mol Des       Date:  2011-10-04       Impact factor: 3.686

3.  Antimicrobials and the risk of torsades de pointes: the contribution from data mining of the US FDA Adverse Event Reporting System.

Authors:  Elisabetta Poluzzi; Emanuel Raschi; Domenico Motola; Ugo Moretti; Fabrizio De Ponti
Journal:  Drug Saf       Date:  2010-04-01       Impact factor: 5.606

4.  The protease inhibitor atazanavir blocks hERG K(+) channels expressed in HEK293 cells and obstructs hERG protein transport to cell membrane.

Authors:  Sheng-na Han; Xiao-yan Sun; Zhao Zhang; Li-rong Zhang
Journal:  Acta Pharmacol Sin       Date:  2015-03-23       Impact factor: 6.150

5.  QTc interval prolongation in patients with HIV and AIDS.

Authors:  Mahmoud U Sani; Basil N Okeahialam
Journal:  J Natl Med Assoc       Date:  2005-12       Impact factor: 1.798

6.  The design and implementation of A5146, a prospective trial assessing the utility of therapeutic drug monitoring using an inhibitory quotient in antiretroviral-experienced HIV-infected patients.

Authors:  Lisa M Demeter; A Lisa Mukherjee; Robin DiFrancesco; Hongyu Jiang; Robert DiCenzo; Barbara Bastow; Alex R Rinehart; Gene D Morse; Mary Albrecht
Journal:  HIV Clin Trials       Date:  2008 Jan-Feb

7.  A probabilistic approach for the evaluation of pharmacological effect induced by patient irregular drug intake.

Authors:  Jun Li; Fahima Nekka
Journal:  J Pharmacokinet Pharmacodyn       Date:  2009-06-25       Impact factor: 2.745

8.  QT dispersion in HIV-infected patients receiving combined antiretroviral therapy.

Authors:  Wanwarang Wongcharoen; Somkhuan Suaklin; Nualnit Tantisirivit; Arintaya Phrommintikul; Nipon Chattipakorn
Journal:  Ann Noninvasive Electrocardiol       Date:  2014-04-21       Impact factor: 1.468

9.  Relationship between HIV protease inhibitors and QTc interval duration in HIV-infected patients: a cross-sectional study.

Authors:  Beny Charbit; Arnaud Rosier; Diane Bollens; Franck Boccara; Pierre-Yves Boelle; Afef Koubaa; Pierre-Marie Girard; Christian Funck-Brentano
Journal:  Br J Clin Pharmacol       Date:  2008-11-17       Impact factor: 4.335

10.  Acquired Long QT Syndrome and Torsade de Pointes Associated with HIV Infection.

Authors:  Alexander Shimabukuro-Vornhagen; Jan Rybniker; Shahram Zoghi; Gerd Faetkenheuer; Guido Michels; Erland Erdmann; Michael von Bergwelt-Baildon; Matthias Kochanek
Journal:  Case Rep Med       Date:  2010-08-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.